Company news
TransCode Therapeutics, Inc. news in 2025
TransCode Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
December 22, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
December 11, 2025
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
November 17, 2025
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
October 14, 2025
TransCode Therapeutics announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences
October 9, 2025
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
October 8, 2025
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
May 28, 2025
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
May 8, 2025
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
May 5, 2025
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
May 2, 2025
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
May 1, 2025
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
May 1, 2025
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
April 21, 2025
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
March 27, 2025
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
March 25, 2025
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 23, 2025
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
March 13, 2025
TransCode Therapeutics, Inc. Announces Results of Special Meeting
February 25, 2025
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
February 5, 2025
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
January 13, 2025
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
January 7, 2025
Decks in 2025
- Investor Presentation (December 2025)
Investor deck · 28 slides · Dec 18, 2025
- Investor Presentation (October 2025)
Investor deck · 35 slides · Oct 8, 2025
- Investor Presentation (May 2025)
Investor deck · 35 slides · May 23, 2025